Amicus Therapeutics Inc.says it is pursuing a broad label for full approval of its oral migalastat in Fabry disease after announcing that FDA rejected its plan for accelerated approval and called for a new trial.
Migalastat is designed to selectively and reversibly bind with high affinity to the active sites of certain mutant forms of...







